RARE vs XERS
RARE: Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases. XERS: A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug formulation platform for rare diseases.
Side-by-side fundamentals
| Metric | RARE | XERS | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $26.04 | $8.42 | |
| Market cap as of 2026-07-31 | $2.6B | $1.5B | |
| P/E as of 2026-07-31 | n/a | 151.71 | |
| PEG as of 2026-07-31 | -1.07 | 2.29 | RARE lower |
| Net margin as of 2026-07-31 | -91.0% | +3.8% | XERS higher |
| Gross margin as of 2026-07-31 | +83.6% | +85.9% | XERS higher |
| Operating margin as of 2026-07-31 | -83.8% | +11.4% | XERS higher |
| ROE as of 2026-07-31 | -414.2% | +99.7% | XERS higher |
| ROA as of 2026-07-31 | -45.7% | +3.2% | XERS higher |
| Debt / equity as of 2026-07-31 | 90.54 | 17.00 | XERS lower |
| Revenue growth (YoY) as of 2026-07-31 | +13.3% | +41.5% | XERS higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | +38.3% | XERS higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-31 | 0.99 | 1.02 | |
| 1-year return as of 2026-07-30 close | -4.1% | +64.1% | XERS higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.